TY - JOUR
KW - Anticoagulants
KW - Apixaban
KW - Atrial fibrillation
KW - Cprd
KW - Dabigatran
KW - Edoxaban
KW - Rivaroxaban
KW - Stroke prevention and control
KW - United Kingdom
AU - A. Khachatryan
AU - I. Doobaree
AU - G. Spentzouris
AU - G. Gusto
AU - Y. Zawaneh
AU - F. Mughal
AU - A. Anastassopoulou
AU - M. Manu
AU - M. Fay
AD - Evidence and Access, Certara, London, UK.
Daiichi Sankyo Europe, Munich, Germany.
Evidence and Access, Certara, Paris, France.
Daiichi Sankyo UK, Uxbridge, UK.
Daiichi Sankyo Europe, Munich, Germany. Anastassia.Anastassopoulou@daiichi-sankyo.eu.
Warwick Medical School, Warwick University, Warwick, UK.
The Willows Medical Practice, Bradford, UK.
AN - 36399317
BT - Adv Ther
DO - 10.1007/s12325-022-02368-y
DP - NLM
ET - 2022/11/19
LA - eng
N1 - 1865-8652
Khachatryan, Artak
Doobaree, Indraraj Umesh
Spentzouris, George
Gusto, Gaelle
Zawaneh, Yousef
Mughal, Farhan
Anastassopoulou, Anastassia
Manu, Marius
Fay, Matthew
Journal Article
United States
Adv Ther. 2022 Nov 18. doi: 10.1007/s12325-022-02368-y.
PY - 2022
SN - 0741-238x
T2 - Adv Ther
TI - Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database
ER -